echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Roche Huntington’s ASO Phase III clinical trial stopped

    Roche Huntington’s ASO Phase III clinical trial stopped

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Roche announced that the Huntington’s disease trans-nucleic acid therapy tominersen (formerly known as IONIS-HTTRx, RG6042) acquired from Ionis has been suspended in the Phase III clinical GENERATION HD1 trial.


    Drug source analysis

    Drug source analysis

    Huntington's disease was first discovered in 1872 by a doctor called Huntington's disease.


    Huntington's disease usually occurs in the adulthood of the patient.


    Many rare genetic diseases appear in childhood, such as SMA, but some also occur in young adults.


    These rare diseases used to be the domain of small biopharmaceutical companies, but with the soaring price of rare disease drugs and the increase in the efficacy requirements of the payment department, large pharmaceutical companies have also entered these fields.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.